Chisa Murazawa

Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more.

M. Ohtani, H. Houchi, H. Yokomise, 2013, Molecular and clinical oncology.

Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes.

M. Ohtani, H. Houchi, H. Yokomise, 2016, Molecular and clinical oncology.

Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance

T. Ishida, A. Yamauchi, H. Imachi, 2010, Breast Cancer Research and Treatment.

Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer

R. Haba, A. Yamauchi, M. Ohtani, 2013, Cancer biology & therapy.

Status and prognostic value of immunological biomarkers of breast cancer

R. Haba, T. Matsunaga, K. Teramoto, 2023, Oncology letters.

Factors responsible for long-term survival in metastatic breast cancer

M. Ohtani, H. Houchi, H. Yokomise, 2014, World Journal of Surgical Oncology.